ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HIK Hikma Pharmaceuticals Plc

1,813.00
-6.00 (-0.33%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.00 -0.33% 1,813.00 1,810.00 1,811.00 1,838.00 1,804.00 1,818.00 365,955 16:35:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.88B 192M 0.8685 20.85 4B
Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,819p. Over the last year, Hikma Pharmaceuticals shares have traded in a share price range of 1,711.00p to 2,222.00p.

Hikma Pharmaceuticals currently has 221,081,676 shares in issue. The market capitalisation of Hikma Pharmaceuticals is £4 billion. Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 20.85.

Hikma Pharmaceuticals Share Discussion Threads

Showing 376 to 398 of 1875 messages
Chat Pages: Latest  27  26  25  24  23  22  21  20  19  18  17  16  Older
DateSubjectAuthorDiscuss
28/7/2016
15:15
Boring share.
r ball
26/7/2016
13:32
This just seems to be going up which is nice so assume that the take over going well and seems to have good news flow but of course some stage will go down question is when
mrthomas
22/7/2016
14:31
ah...the trend is your friend as they say...until it breaks.
r ball
22/7/2016
13:31
Fair enough. I read an article in the Motley Fool saying weak GBP benefits Hikma. It really doesn't, apart from the FX translation (as GBP drops, it looks cheaper in USD terms). Dangerous levels here - so much priced in and stock grinding higher on ever-decreasing volumes.
rrb
22/7/2016
13:20
Sorry. meant GBP hedge. as £ drops share price rises.
r ball
22/7/2016
11:57
how can a company earning in USD with a large cost base in USD and reporting in USD be a USD hedge?!
rrb
21/7/2016
07:31
Gets better. Fwiw. Look at fx effect on halma
r ball
20/7/2016
19:09
I'm alone here.
r ball
15/7/2016
18:37
Inverse relationship to nos of posts
r ball
15/7/2016
10:12
and that as well looking to keep this a a long term hold if possible but am surprised at how little following has
mrthomas
06/7/2016
18:26
Agree these are doing very well and saw a report from a good broker saying they impressed with the company and see more upside which is good
mrthomas
01/7/2016
15:54
staggeringly few comments.
r ball
01/7/2016
11:52
They entered the FTSE 100 on 20 June.

Fund buying to adjust weightings.

broadwood
01/7/2016
11:46
there is a lot m ore to go here. Watch sector rotation from property into pharma.

also watch for more business friendly climate. PPI deadline (coming), Living wage (abandoned) etc.

r ball
01/7/2016
10:51
could be Middle East factor but done very well on this share in past 4 months see your logic re ex rate $ taking to higher at least will keep it in Top 100
mrthomas
30/6/2016
21:59
£28 target (well £25 using last weeks $ krona rate)
r ball
30/6/2016
18:47
why is this share so overlooked??
r ball
28/6/2016
18:35
Its a $ hedge with a stable income stream. Expecting it to be up 15% in current market.

More upside to come.

More to go.

r ball
28/6/2016
13:37
Be surprised how well doing was thinking of selling as done very well on this stock in 4 months
mrthomas
28/6/2016
11:38
safe haven. $ denominated earnings.
r ball
06/6/2016
15:18
Jordanian drugs-maker Hikma became the fourth pharma constituent of the FTSE 100 in March 2015, before falling out of favour with investors and dropping out of the top index a year later. But a recent positive trading statement has seen the share price rally enormously and last month the group rejoined the FTSE 100 having replaced satellite firm Insmarsat.
broadwood
02/6/2016
19:35
quite. hold.ps; ftse up 0.8% in past 12 months. if you beat this you are doing very very well
r ball
02/6/2016
07:32
Should keep bubbling along as Fund Managers up their weightings.

Hikma Pharmaceuticals is set to enter the FTSE 100 index as satellite firm Inmarsat drops to the FTSE 250.

The changes will take effect on June 20, London Stock Exchange said today.

Hikma Pharmaceuticals's promotion to Britain's blue chip index comes after its shares surged 45 per cent since mid-March. The company expects its full year group revenue to be between $2bn (£1.3bn) and $2.1bn (£1.4bn

broadwood
Chat Pages: Latest  27  26  25  24  23  22  21  20  19  18  17  16  Older

Your Recent History

Delayed Upgrade Clock